Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 PURCHASE, N.Y., Oct. 01, 2024 ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

Lewy body dementia is a progressive neurodegenerative disorder brought on by an excess of the protein alpha-synuclein in the brain. These deposits, known as Lewy bodies, can inhibit the production of ...

Attention-deficit/hyperactivity disorder (ADHD) in adults is independently associated with an increased risk for dementia with Lewy bodies (DLB), dementia, and ...

The MarketWatch News Department was not involved in the creation of this content. According to DelveInsight's analysis, the Lewy body dementia market is anticipated to increase during the forecast ...

The Penguin recently aired its sixth episode. The episode was filled with interesting twists and turns, leaving viewers on the edge of their seats. One of the major revelations made in the episode was ...

PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative ...

PURCHASE, N.Y., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX), (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company ...